KEGG DRUG

Search results

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY	Disease ID
1	150 mg double-blinded secukinumab	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
2	150 mg open-label secukinumab	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
3	300 mg double-blinded secukinumab	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
4	SECUKINUMAB	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[8] 13, 37, 41, 46, 107, 160, 269, 271 💬
5	Secukinumab (150 mg)	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
6	Secukinumab (75 mg)	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
7	Secukinumab (AIN457)	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 46 💬
8	Secukinumab (AIN457) 150 mg s.c.	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
9	Secukinumab 150 mg	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 41 💬
10	Secukinumab 150 mg (2 injections per dose	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 269 💬
11	Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
12	Secukinumab 150 mg/1 mL Solution for injection	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[2] 37, 271 💬
13	Secukinumab 150 mg/ml	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
14	Secukinumab 150 milligram [Cosentyx]	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
15	Secukinumab 150mg	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 37 💬
16	Secukinumab 300 mg	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 41 💬
17	Secukinumab 300 mg, s.c.	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 41 💬
18	Secukinumab 300mg	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 37 💬
19	Secukinumab 75 mg/0.5 ml Solution for injection	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 271 💬
20	Secukinumab Injection	[1] Secukinumab	[1] Secukinumab 💬	[1] IL17A 💬	[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬	[1] 160 💬